A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
- Conditions
- Vitiligo
- Interventions
- Registration Number
- NCT06118411
- Lead Sponsor
- AbbVie
- Brief Summary
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo (NSV). Adverse effects and change in disease activity will be assessed.
Upadacitinib is an approved drug for various immune-mediated inflammatory diseases and is currently being investigated for the treatment of NSV. There will be 2 replicate studies running at the same time (Study 1 and Study 2 with periods A and B) and an optional exploratory Narrow-Band Ultraviolet B (NB-UVB) phototherapy study (Study 3). In Period A, participants are placed in 1 of 2 groups called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will receive placebo and 2 in 3 chance participants will receive upadacitinib. In Period B, all participants will receive upadacitinib. Approximately 270 adult and adolescent participants with NSV will be enrolled in each main study ((Study 1 and Study 2, 540 subjects total) at approximately 90 sites worldwide with an option for adult participants who completed Period A of either study and did not achieve T-VASI 90 at week 48 while on study drug, to enter Study 3.
In Studies 1 and 2: Period A, participants will receive oral tablets of upadacitinib or placebo once a day for 48 weeks. In Period B, participants will receive oral tablets of upadacitinib 15 mg once a day for 112 weeks. Participants will be followed up for 30 days. Study 3 participants will receive upadacitinib monotherapy or upadacitinib with NB-UBV phototherapy for at least 24 weeks followed by upadacitinib alone.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 614
-
Documented clinical diagnosis of non-segmented vitiligo (NSV).
-
At Screening and Baseline Visits, participants must satisfy at least 1 of the following criteria:
- >= 0.5 F-VASI and 5 <= T-VASI < 50 AND have failed at least 1 topical corticosteroid and/or at least 1 topical calcineurin inhibitor for vitiligo; or
- >= 0.5 F-VASI and 5 <= T-VASI < 50 AND have a sign of actively progressing vitiligo; or
- >= 0.5 F-VASI and 10 <= T-VASI < 50.
- Segmental or localized vitiligo.
- History of active skin disease other than vitiligo that could interfere with the assessment of vitiligo.
- >33% leukotrichia in areas of vitiligo on the face or > 33% leukotrichia in areas of vitiligo on the body (including the face).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Study 1, Period B: Group 1 Open-Label Extension Period Upadacitinib Participants that were randomized to receive upadacitinib in Period A Group 1, will continue to receive upadacitinib 15 mg once daily for 112 weeks in Period B. Study 1, Period B: Group 2 Open-Label Extension Period Upadacitinib Participants that were randomized to receive placebo in Period A Group 2, will receive upadacitinib 15 mg once daily for 112 weeks in Period B. Study 2, Period B: Group 1 Open-Label Extension Period Upadacitinib Participants that were randomized to receive upadacitinib in Period A Group 1, will continue to receive upadacitinib 15 mg once daily for 112 weeks in Period B. Study 2, Period B: Group 2 Open-Label Extension Period Upadacitinib Participants that were randomized to receive placebo in Period A Group 2, will receive upadacitinib 15 mg once daily for 112 weeks in Period B. (Optional) Study 3, Period B: Open Label Upadacitinib Upadacitinib Open Label Upadacitinib Participants will receive upadacitinib 15 mg once daily for 112 weeks (Optional) Study 3, Period B: Open Label Upadacitinib NB-UVB (narrow-band ultraviolet B) Phototherapy Open Label Upadacitinib Participants will receive upadacitinib 15 mg once daily for 112 weeks (Optional) Study 3: Upadacitinib Participants will receive 15 mg upadacitinib once daily for 112 weeks and NB-UVB for up to 28 weeks (Optional) Study 3: NB-UVB (narrow-band ultraviolet B) Phototherapy Participants will receive 15 mg upadacitinib once daily for 112 weeks and NB-UVB for up to 28 weeks Study 1, Period A: Group 1 Upadacitinib Participants will receive upadacitinib 15 mg once daily for 48 weeks. Study 1, Period A: Group 2 Placebo Participants will receive placebo once daily for 48 weeks. Study 2, Period A: Group 1 Upadacitinib Participants will receive upadacitinib 15 mg once daily for 48 weeks. Study 2, Period A: Group 2 Placebo Participants will receive placebo once daily for 48 weeks.
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 (≥ 50% Improvement in T-VASI From Baseline) Week 48 The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100.
Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index (F-VASI) 75 (≥ 75% Improvement in F-VASI From Baseline) Week 48 The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Achieving F-VASI 50 (≥ 50% Improvement in F-VASI From Baseline) Week 48 The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.
Percentage of Participants Achieving F-VASI 75 (≥ 75% Improvement in F-VASI From Baseline) Week 24 The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.
Percent Change from Baseline in F-VASI Week 24 The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.
Percent Change From Baseline in T-VASI Week 48 The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100.
Percentage of Participants Achieving F-VASI 90 (≥ 90% Improvement in F-VASI From Baseline) Week 48 The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.
Percentage of Participants Achieving T-VASI 75 (≥ 75% Improvement in T-VASI From Baseline) Week 48 The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100.
Percentage of Participants Achieving 3D Imaging Facial Vitiligo 40 (≥ 40% Reduction in Facial Vitiligo Area Measured by 3D Digital Imaging from Baseline) (Study 1 Only) Week 48 3D imaging will be used to objectively quantify the facial vitiligo area.
EU/EMA Only: Percentage of Participants Achieving a Physician's Global Impression of Change - Vitiligo (PhGIC-V) of "Much better (1)" At Week 48 The physician rates the overall change in the patients vitiligo by comparing the severity of vitiligo right now with the severity of vitiligo since the subject started the study treatment. Responses range from 1 = "Much better" to 5 = "Much worse."
EU/EMA Only: Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) score of "A lot less noticeable (4)" or "No longer noticeable (5)" At Week 48 The VNS is a single-item, validated questionnaire used in clinical trials to assess the noticeability of vitiligo lesions following therapy. The item is scored on a 5-point scale: 1 = more noticeable; 2 = as noticeable; 3 = slightly less noticeable; 4 = a lot less noticeable; and 5 = no longer noticeable. A score of 4 or 5 represents treatment success
EU/EMA Only: Percentage of Participants Achieving a Patient's Global Impression of Change-Vitiligo (PaGIC-V) of "Much better (1)" At Week 48 The PaGIC-V asks participants to rate the overall change in their vitiligo by comparing the severity of their vitiligo right now with the severity of their vitiligo since they started the study treatment. Responses range from 1 = "Much better" to 5 = "Much worse."
Trial Locations
- Locations (148)
Joseph Raoof Md,Inc /Id# 260055
🇺🇸Encino, California, United States
Alliance Dermatology and Mohs Center /ID# 259926
🇺🇸Phoenix, Arizona, United States
University of California Irvine /ID# 260080
🇺🇸Irvine, California, United States
Stanford University /ID# 260081
🇺🇸Redwood City, California, United States
University of California Davis Health /ID# 260062
🇺🇸Sacramento, California, United States
Skin Care Research Boca Raton /ID# 260094
🇺🇸Boca Raton, Florida, United States
Direct Helpers Research Center /ID# 259932
🇺🇸Hialeah, Florida, United States
Encore Medical Research /ID# 259963
🇺🇸Hollywood, Florida, United States
Encore Medical Research - Weston /ID# 260542
🇺🇸Weston, Florida, United States
Cleaver Medical Group Dermatology /ID# 259925
🇺🇸Dawsonville, Georgia, United States
Indiana University Health University Hospital /ID# 259974
🇺🇸Indianapolis, Indiana, United States
Tufts Medical Center /ID# 260088
🇺🇸Boston, Massachusetts, United States
UMass Memorial Medical Center /ID# 259921
🇺🇸Worcester, Massachusetts, United States
Great Lakes Research Group - Bay City /ID# 260600
🇺🇸Bay City, Michigan, United States
Clarkston Dermatology /ID# 260069
🇺🇸Clarkston, Michigan, United States
Henry Ford Medical Center - New Center One /ID# 260059
🇺🇸Detroit, Michigan, United States
Vivida Dermatology- Flamingo /ID# 260609
🇺🇸Las Vegas, Nevada, United States
Icahn School of Medicine at Mount Sinai /ID# 259909
🇺🇸New York, New York, United States
Oregon Medical Research Center /ID# 259911
🇺🇸Portland, Oregon, United States
Medical University of South Carolina /ID# 259916
🇺🇸Charleston, South Carolina, United States
Innovative Dermatology - Plano /ID# 260628
🇺🇸Plano, Texas, United States
Dermatology Clinical Research Center of San Antonio /ID# 260047
🇺🇸San Antonio, Texas, United States
Instituto de Neumonologia y Dermatologia /ID# 259888
🇦🇷Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
Buenos Aires Skin /ID# 259885
🇦🇷Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
Psoriahue Med Interdisciplinar /ID# 259890
🇦🇷Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
Instituto De Investigaciones Clínicas Córdoba /ID# 260371
🇦🇷Córdoba, Cordoba, Argentina
Sanatorio 9 de Julio /ID# 260245
🇦🇷San Miguel de Tucumán, Tucuman, Argentina
Centro de Investigacion y Prevencion Cardiovascular (CIPREC) /ID# 259889
🇦🇷Buenos Aires, Argentina
Cliniques Universitaires UCL Saint-Luc /ID# 259429
🇧🇪Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium
Grand Hopital de Charleroi /ID# 259437
🇧🇪Charleroi, Hainaut, Belgium
UZ Gent /ID# 259430
🇧🇪Gent, Oost-Vlaanderen, Belgium
CHU de Liege /ID# 259427
🇧🇪Liege, Belgium
Medical Center Cordis /ID# 259954
🇧🇬Pleven, Bulgaria
Ambulatory for Specialized Medical Care for skin and venereal diseases /ID# 259955
🇧🇬Sofia, Bulgaria
Diagnostic consultative center Focus-5 /ID# 259956
🇧🇬Sofiya, Bulgaria
XX Diagnostic consultative center Sofia EOOD /ID# 259953
🇧🇬Sofiya, Bulgaria
Dermatology Research Institute - Blackfoot Trail /ID# 261175
🇨🇦Calgary, Alberta, Canada
Dr. Chih-ho Hong Medical Inc. /ID# 260239
🇨🇦Surrey, British Columbia, Canada
Wiseman Dermatology Research /ID# 260236
🇨🇦Winnipeg, Manitoba, Canada
Brunswick Dermatology Center /ID# 260237
🇨🇦Fredericton, New Brunswick, Canada
LEADER Research /ID# 260407
🇨🇦Hamilton, Ontario, Canada
Private Practice - Dr. Kim Papp Clinical Research /ID# 260406
🇨🇦Waterloo, Ontario, Canada
Centre de Recherche dermatologique du Quebec Metropolitain /ID# 260241
🇨🇦Québec, Quebec, Canada
Dre Angelique Gagne-Henley M.D. inc. /ID# 260238
🇨🇦Saint-Jerome, Quebec, Canada
Beijing Tongren Hospital Affiliated To Capital Medical University /ID# 260919
🇨🇳Beijing, Beijing, China
Dermatology Hospital of Southern Medical University /ID# 260136
🇨🇳Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University /ID# 259929
🇨🇳Guangzhou, Guangdong, China
Renmin Hospital of Wuhan University /ID# 260477
🇨🇳Wuhan, Hubei, China
Second Affiliated Hospital of Xian Jiaotong University /ID# 260011
🇨🇳Xi'an, Shaanxi, China
The First Affiliated Hospital of Xi'an Jiaotong University /ID# 260340
🇨🇳Xian, Shaanxi, China
Shandong Dermatological Hospital /ID# 260338
🇨🇳Jinan, Shandong, China
Huashan Hospital, Fudan University /ID# 259823
🇨🇳Shanghai, Shanghai, China
Chengdu Second Municipal People's Hospital /ID# 260423
🇨🇳Chengdu, Sichuan, China
West China Hospital, Sichuan University /ID# 260624
🇨🇳Chengdu, Sichuan, China
Tianjin Medical University General Hospital /ID# 259812
🇨🇳Tianjin, Tianjin, China
First Affiliated Hospital of Kunming Medical University /ID# 260017
🇨🇳Kunming, Yunnan, China
Hangzhou Third People's Hospital /ID# 261005
🇨🇳Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine /ID# 260626
🇨🇳Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University /ID# 259822
🇨🇳Wenzhou, Zhejiang, China
Chu de Nice-Hopital Larchet Ii /Id# 259442
🇫🇷Nice, Alpes-Maritimes, France
Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Saint-Andre /ID# 259443
🇫🇷Bordeaux, Gironde, France
Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 259446
🇫🇷Creteil, Paris, France
HCL - Hopital Edouard Herriot /ID# 259444
🇫🇷Lyon, Rhone, France
Universitaetsklinikum Muenster /ID# 260147
🇩🇪Muenster, Nordrhein-Westfalen, Germany
CHU Toulouse - Hopital Larrey /ID# 259445
🇫🇷Toulouse, France
Universitaetsklinikum Erlangen /ID# 260153
🇩🇪Erlangen, Bayern, Germany
Universitaetsmedizin Mainz /ID# 260151
🇩🇪Mainz, Rheinland-Pfalz, Germany
Dermatologische Gemeinschaftspraxis Mahlow /ID# 260148
🇩🇪Blankenfelde-Mahlow, Brandenburg, Germany
MVZ Dermatologisches Zentrum Bonn GmbH /ID# 260287
🇩🇪Bonn, Hessen, Germany
Universitaetsklinikum Frankfurt /ID# 260288
🇩🇪Frankfurt am Main, Hessen, Germany
Fachklinik Bad Bentheim /ID# 260293
🇩🇪Bad Bentheim, Niedersachsen, Germany
Private Practice - Dr. Abdou Zarzour /ID# 260290
🇩🇪Halle, Sachsen-Anhalt, Germany
Universitaetsklinikum Carl Gustav Carus Dresden /ID# 260289
🇩🇪Dresden, Sachsen, Germany
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 260294
🇩🇪Berlin, Germany
Klinikum rechts der Isar /ID# 260291
🇩🇪Munich, Germany
DERMA-B Egeszsegugyi es Szolgaltato - Debrecen - Gyepusor Utca /ID# 260072
🇭🇺Debrecen, Hungary
Rambam Health Care Campus /ID# 259852
🇮🇱Haifa, H_efa, Israel
The Chaim Sheba Medical Center /ID# 259851
🇮🇱Ramat Gan, Tel-Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 259850
🇮🇱Tel Aviv, Tel-Aviv, Israel
Hadassah Medical Center-Hebrew University /ID# 259849
🇮🇱Jerusalem, Yerushalayim, Israel
Rabin Medical Center /ID# 260420
🇮🇱Haifa, Israel
IRCCS Istituti Fisioterapici Ospitalieri-Istituto Dermatologico San Gallicano /ID# 259771
🇮🇹Rome, Roma, Italy
ASST degli Spedali Civili di Brescia /ID# 259772
🇮🇹Brescia, Italy
Nagoya City University Hospital /ID# 260551
🇯🇵Nagoya shi, Aichi, Japan
Osaka University Hospital /ID# 261285
🇯🇵Suita-shi, Osaka, Japan
Nippon Medical School Hospital /ID# 260550
🇯🇵Bunkyo-ku, Tokyo, Japan
Chungnam National University Hospital /ID# 260917
🇰🇷Daejeon, Daejeon Gwang Yeogsi, Korea, Republic of
Soon Chun Hyang University Hospital Bucheon /ID# 260836
🇰🇷Bucheon-si, Gyeonggido, Korea, Republic of
Ajou University Hospital /ID# 260916
🇰🇷Suwon-si, Gyeonggido, Korea, Republic of
The Catholic University Of Korea St. Vincent's Hospital /ID# 260880
🇰🇷Suwon, Gyeonggido, Korea, Republic of
Kyung Hee University Hospital at Gangdong /ID# 260879
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Bravis Ziekenhuis /ID# 259501
🇳🇱Bergen op Zoom, Noord-Brabant, Netherlands
Amphia Ziekenhuis /ID# 259696
🇳🇱Breda, Noord-Brabant, Netherlands
Amsterdam UMC, locatie AMC /ID# 259676
🇳🇱Amsterdam, Noord-Holland, Netherlands
Dermodent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski /ID# 259690
🇵🇱Osielsko, Kujawsko-pomorskie, Poland
Specjalistyczny Gabinet Dermatologiczny Aplikacyjno Badawczy /ID# 260016
🇵🇱Krakow, Malopolskie, Poland
Malopolskie Centrum Kliniczne /ID# 259686
🇵🇱Krakow, Malopolskie, Poland
Krakowskie Centrum Medyczne /ID# 261424
🇵🇱Krakow, Malopolskie, Poland
Klinika Ambroziak Dermatologia /ID# 260018
🇵🇱Warszawa, Mazowieckie, Poland
Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 259753
🇵🇱Bialystok, Podlaskie, Poland
Centrum Medyczne Angelius Provita /ID# 259752
🇵🇱Katowice, Slaskie, Poland
Twoja Przychodnia SCM /ID# 259757
🇵🇱Szczecin, Zachodniopomorskie, Poland
Unidade Local de Saude de Coimbra, EPE /ID# 259793
🇵🇹Coimbra, Portugal
Unidade Local de Saude da Regiao de Leiria, EPE /ID# 259789
🇵🇹Leiria, Portugal
Royalderm Agnieszka Nawrocka /ID# 259691
🇵🇱Warsaw, Mazowieckie, Poland
Klinika Osipowicz & Turkowski sp.z.o.o /ID# 259761
🇵🇱Warszawa, Mazowieckie, Poland
Hospital CUF Descobertas /ID# 259788
🇵🇹Lisboa, Portugal
Unidade Local de Saude de Santo Antonio, E.P.E. /ID# 259791
🇵🇹Porto, Portugal
Santa Cruz Behavioral (SCB) Research Center /ID# 260100
🇵🇷Bayamon, Puerto Rico
Derma therapy spol /ID# 260838
🇸🇰Bratislava, Bratislavsky Kraj, Slovakia
Fakultna nemocnica Trnava /ID# 260164
🇸🇰Trnava, Slovakia
Hospital Universitario Clinico San Cecilio /ID# 259374
🇪🇸Granada, Spain
Grupo Pedro Jaen /ID# 259375
🇪🇸Madrid, Spain
Hospital Universitario Germans Trias i Pujol /ID# 259371
🇪🇸Badalona, Barcelona, Spain
Hospital Universitario de Getafe /ID# 259376
🇪🇸Getafe, Madrid, Spain
Hospital Universitario Quironsalud Madrid /ID# 259377
🇪🇸Pozuelo de Alarcon, Madrid, Spain
Consorci Hospital General Universitario de Valencia /ID# 259372
🇪🇸Valencia, Spain
Hospital Clinico Universitario Lozano Blesa /ID# 259373
🇪🇸Zaragoza, Spain
Advanced Research Associates - Glendale /ID# 259915
🇺🇸Glendale, Arizona, United States
Dermatology Research Associates /ID# 260056
🇺🇸Los Angeles, California, United States
Integrative Skin Science and Research /ID# 260060
🇺🇸Sacramento, California, United States
Clinical Trials Research Institute /ID# 259910
🇺🇸Thousand Oaks, California, United States
Apex Clinical Trials /ID# 260096
🇺🇸Brandon, Florida, United States
Vitiligo & Pigmentation Institute of Southern California /ID# 259970
🇺🇸Los Angeles, California, United States
Florida Academic Dermatology Center /ID# 259919
🇺🇸Coral Gables, Florida, United States
GSI Clinical Research, LLC /ID# 259918
🇺🇸Margate, Florida, United States
Skin Care Research - Hollywood /ID# 260101
🇺🇸Hollywood, Florida, United States
Life Clinical Trials /ID# 260097
🇺🇸Margate, Florida, United States
Savin Medical Group, LLC /ID# 259968
🇺🇸Miami Lakes, Florida, United States
Advanced Clinical Research Institute /ID# 260058
🇺🇸Tampa, Florida, United States
DeNova Research /ID# 260611
🇺🇸Chicago, Illinois, United States
Dawes Fretzin, LLC /ID# 260068
🇺🇸Indianapolis, Indiana, United States
Oakland Hills Dermatology /ID# 260602
🇺🇸Auburn Hills, Michigan, United States
Hamzavi Dermatology - Canton /ID# 260545
🇺🇸Canton, Michigan, United States
Minnesota Clinical Study Center /ID# 260154
🇺🇸New Brighton, Minnesota, United States
Schweiger Dermatology, P.C. /ID# 260152
🇺🇸New York, New York, United States
DermResearchCenter of New York, Inc. /ID# 259906
🇺🇸Stony Brook, New York, United States
Oregon Dermatology and Research Center /ID# 259917
🇺🇸Portland, Oregon, United States
Bellaire Dermatology Associates /ID# 260044
🇺🇸Bellaire, Texas, United States
ClinOhio Research Services /ID# 260300
🇺🇸Columbus, Ohio, United States
Dermatology Treatment and Research Center /ID# 260078
🇺🇸Dallas, Texas, United States
Progressive Clinical Research /ID# 260070
🇺🇸San Antonio, Texas, United States
Dermatology and Ophthalmology Kume Clinic /ID# 260555
🇯🇵Sakai-shi, Osaka, Japan
Tokyo Medical University Hospital /ID# 260552
🇯🇵Shinjuku-ku, Tokyo, Japan
Yamagata University Hospital /ID# 260553
🇯🇵Yamagata-shi, Yamagata, Japan
Yamanashi Prefectural Central Hospital /ID# 260554
🇯🇵Kofu-shi, Yamanashi, Japan
Dr. Samuel Sanchez PSC /ID# 260090
🇵🇷Caguas, Puerto Rico
Mindful Medical Research /ID# 260092
🇵🇷San Juan, Puerto Rico
Related News
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis ...
- Prev
- 1
- Next